WHWKHIGH SIGNALFINANCIAL10-K

WHWK experienced a substantial decline in revenue while R&D expenses grew meaningfully, indicating a strategic pivot toward increased drug development investment despite reduced commercial performance.

The company has successfully advanced two drug candidates (HWK-007 and HWK-016) through FDA IND clearance with Phase 1 trials now recruiting, representing significant regulatory progress. However, the dramatic revenue contraction combined with substantially higher R&D spending creates increased cash burn risk, though the company appears to be prioritizing pipeline advancement over near-term profitability.

Comparing 2026-03-12 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows a company in transition, with revenue declining substantially while R&D expenses grew meaningfully to $91M, reflecting heightened investment in drug development. Operating cash outflows increased significantly to $97.4M, though this was partially offset by improved net income due to non-operating factors. Despite the increased cash burn, the company maintained a solid cash position of $37.6M and reduced total liabilities, suggesting adequate liquidity to fund ongoing clinical operations in the near term.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
+78.3%
$51.0M$91.0M

R&D investment increased 78.3% — signals commitment to future product development, though near-term margin impact.

Revenue
P&L
-72.5%
$26.0M$7.1M

Revenue declined 72.5% — significant demand weakness or market share loss warrants investigation.

Operating Income
P&L
-69.6%
-$67.5M-$114.4M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
+67.7%
-$63.7M-$20.6M

Net income grew 67.7% — bottom-line growth signals improving overall business health.

Capital Expenditure
Cash Flow
-66.6%
$1.7M$552K

Capex reduced 66.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
-63.6%
-$59.5M-$97.4M

Operating cash flow fell 63.6% — earnings quality concerns; investigate working capital changes and non-cash items.

Cash & Equivalents
Balance Sheet
+31%
$28.7M$37.6M

Cash position surged 31% — strong cash generation or capital raise providing significant financial cushion.

SG&A Expense
P&L
-18.8%
$36.7M$29.8M

SG&A reduced 18.8% — improved cost efficiency or headcount reduction improving operating margins.

Total Liabilities
Balance Sheet
-18.6%
$17.8M$14.5M

Liabilities reduced 18.6% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-15%
$17.1M$14.5M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-28
ADDED
In December 2024, we entered into an intellectual property license agreement (the WuXi License Agreement ) with WuXi Biologics (Shanghai FX) Co., Ltd.
The antibody targeting SEZ6 is a biparatopic SEZ6 ( biSEZ6 ) antibody targeting two different epitopes on SEZ6.
We submitted investigational new drug ( IND ) applications with the U.S.
Food and Drug Administration ( FDA ) for HWK-007 for the treatment of solid tumors, including non-small cell lung cancer ( NSCLC ) and ovarian cancer, and HWK-016 for the treatment of ovarian and endrometrial cancers, in the fourth quarter of 2025; and we anticipate submitting an IND for HWK-206 for the treatment of small cell lung cancer ("SCLC") and neuroendocrine tumors ( NETs ) in mid-2026.
The FDA has cleared the IND applications for HWK-007 and HWK-016 and the Phase 1 trials for each asset are now actively recruiting.
+7 more — sign up free →
REMOVED
We recently entered into an intellectual property license agreement (the WuXi License Agreement ) with WuXi Biologics (Shanghai FX) Co., Ltd.
The antibody targeting SEZ6 is a biparatopic SEZ6 ("biSEZ6") antibody targeting two different epitopes on SEZ6.
We anticipate submitting three investigational new drug ( IND ) applications with the U.S.
Food and Drug Administration ( FDA ) in the coming 12 to 24 months, starting with HWK-007 for the treatment of solid tumors, including non-small cell lung cancer ( NSCLC ) and ovarian cancer, in the second half of 2025; HWK-016 for the treatment of cancers of female origin by the end of 2025; and HWK-206 for the treatment of cancers of neuroendocrine origin in mid-2026.
On February 22, 2022, we launched FYARRO in the United States for treatment of advanced malignant PEComa and recognized net product sales of $26.0 million and $24.4 million for the years ended December 31, 2024 and 2023, respectively.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →